Ranolazine as a therapeutic agent for diabetic cardiomyopathy: reducing endoplasmic reticulum stress and inflammation in type 2 diabetic rat model
Abstract Background Diabetic cardiomyopathy (DCM) is a significant cardiovascular complication of diabetes, characterized by structural and functional heart muscle dysfunction. Oxidative stress, endoplasmic reticulum (ER) stress, and inflammation are pivotal in the pathogenesis of DCM. Ranolazine, p...
Saved in:
| Main Authors: | Matin Mohyadini, Aghele Fahimi, S. Zahra Bathaie, Hamid Yaghooti |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | BMC Pharmacology and Toxicology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40360-025-00945-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
RANOLAZINE IN ISCHEMIC HEART DISEASE
by: V. P. Lupanov
Published: (2015-12-01) -
Effects of ranolazine on angiogenesis and oxidant-antioxidant balance: an in vivo experimental model study
by: Fethullah Kayan, et al.
Published: (2025-07-01) -
Neuroprotective effect of ranolazine in mice's model of Alzheimer's disease
by: Mariam H. Sadiq, et al.
Published: (2024-06-01) -
Neuroprotective role of ranolazine in Parkinson disease: Drosophila melanogaster model
by: Parvesh, et al.
Published: (2025-01-01) -
Cardio-protective role of ranolazine during percutaneous coronary intervention in chronic coronary syndrome patients
by: Ahmed G.Bakry, et al.
Published: (2025-05-01)